Drug combo before and after transplant for high-risk myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed multiple myeloma that is considered high-risk.
- You are between 18 and 75 years old and healthy enough for a stem cell transplant.
- Your cancer has responded at least partially (≥ PR) to your initial treatment.
- You have adequate liver and kidney function (based on blood tests).
- You agree to use effective contraception if you could become pregnant or father a child, and you will not donate blood, sperm, or eggs during the study and for a period after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial tests two treatments (lenalidomide plus elranatamab versus lenalidomide plus daratumumab) as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see which combination is better at keeping the cancer in remission.
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.